Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Archimedes acquires chitosan IP from Fennopharma

Archimedes acquires chitosan IP from Fennopharma

19th September 2008

Archimedes Development, a subsidiary of UK-based Archimedes Pharma, has announced the purchase of an intellectual property (IP) portfolio relating to a number of innovative chemical derivatives of chitosan from Finnish research and development firm Fennopharma.

Included in the deal is IP pertaining to highly water-soluble forms of the bioadhesive polymer derived from natural sources, with Fennopharma giving Archimedes exclusive rights to a number of patents and technical information relating to manufacturing and preclinical development.

Archimedes will contract Fennopharma to synthesis and supply it with chitosan in the short-term.

It said this acquisition will facilitate the extension of applicability of its ChiSys proprietary chitosan-based intranasal drug delivery technology.

Alan Smith, vice-president of research and development at the company, said: “The ChiSys platform has already proven its potential in safely and effectively increasing the nasal bioavailability of a wide range of drugs.”

He added that this deal will allow the company to formulate its ChiSys platform with drugs across a comprehensive range of physiological pH, with the firm delighted to have brought this technology under its direct control.

Last month, Archimedes announced the expansion of its product portfolio with the in-licensing of Oramorph.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.